Skip to main content

01.12.2018 | Research | Ausgabe 1/2018 Open Access

Health and Quality of Life Outcomes 1/2018

Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series

Health and Quality of Life Outcomes > Ausgabe 1/2018
Daniel Buergy, Vincent Schneiberg, Joerg Schaefer, Grit Welzel, Lutz Trojan, Christian Bolenz, Frederik Wenz
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12955-018-0844-8) contains supplementary material, which is available to authorized users.



Patient-reported health-related quality of life (HRQOL) differs between treatment options for prostate carcinoma. Long-term HRQOL data in brachytherapy series are scarce. Therefore, we analyzed prostate-specific and general HRQOL in patients treated with brachytherapy for prostate carcinoma after long-term follow-up.


Two hundred ninety-six patients with prostate carcinoma were treated with brachytherapy (01/1998–11/2003). General and prostate-specific HRQOL were measured using EORTC-QLQ-C30 and EORTC-QLQ-PR25, respectively. Patients were asked to complete the questionnaires after a median follow-up of 141 (119–181) months. QLQ-C30 results were compared to the German reference population. QLQ-PR25 results were compared to an earlier follow-up after a median of 51 months (no published QLQ-PR25 reference population for comparison). Additionally, a literature review on HRQOL data in brachytherapy series was performed.


One hundred six (35.8%) patients were lost to follow-up, 70 (23.6%) had died. 120 (40.5%) patients were contacted. 80 questionnaires were returned (27% of the original cohort; 91% of alive patients were ≥70 years). Sexual activity declined over time (mean scores: 40.5 vs. 45.5; p = 0.006), hormonal treatment-related symptoms, problems associated with incontinence aids, and burden of obstructive urinary symptoms did not differ significantly compared to the 51-month follow-up. General HRQOL was numerically better in our cohort as compared to the German reference population (> 16% relative difference for both age strata; < 70 and ≥70 years).


Our results indicate that symptom-burden after long-term follow-up and associated prostate-specific HRQOL remains relatively stable from 51 to 141 months. General HRQOL in surviving patients was numerically better compared to the reference population.
Additional file 1: Table S1. Clinical studies listed in PubMed on EORTC QLQ-C30 or QLQ-PR25 in prostate carcinoma treated with brachytherapy. (DOCX 51 kb)
Additional file 2: Table S2. Correlations between QLQ-PR25 scores and general quality of life. (DOCX 17 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Health and Quality of Life Outcomes 1/2018 Zur Ausgabe